Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
24 participants
INTERVENTIONAL
2011-09-01
2013-09-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
NCT00462761
A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias
NCT06474663
Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
NCT01408160
Niclosamide in Pediatric Patients With Relapsed and Refractory AML
NCT05188170
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT00983528
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a study of an investigational drug called AC220. AC220 is considered investigational because it has not been approved in the United States by the Food and Drug Administration (FDA). AC220 is a drug which is able to "turn off" the FLT3 grow signal. AC220 will be given with cytarabine and etoposide to treat the relapsed leukemia. This is a phase I study, which means that the study is being done to find the highest dose of AC220 that can be given safely with the drugs cytarabine and etoposide to children and young adults.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ALL AC220 @ 25mg/m2/day (Dose Level 1)
The starting dose is Dose Level 1 at 25 mg/m2/day. Dose escalation will proceed from level 1 to 2 to 3, and so on, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age.
AC220
Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
Cytarabine
All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day "1" of course 1 and 2. Dose defined by age:
* 20 mg for patients age \<1 yr
* 30 mg for patients age 1-1.99 years of age
* 50 mg for patients age 2-2.99 years of age
* 70 mg for patients \>3 years of age
Etoposide
150 mg/m2/day IV on days 1 through 5.
Methotrexate
IT methotrexate given intrathecally to patients with ALL on day "0" of course 1 and 2. Dose defined by age
* 6 mg for patients age \< 1yr
* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age
AML AC220 @ 25mg/m2/day (Dose Level 1)
The starting dose is Dose Level 1 at 25 mg/m2/day. Dose escalation will proceed from level 1 to 2 to 3, and so on, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age.
AC220
Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
Cytarabine
All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day "1" of course 1 and 2. Dose defined by age:
* 20 mg for patients age \<1 yr
* 30 mg for patients age 1-1.99 years of age
* 50 mg for patients age 2-2.99 years of age
* 70 mg for patients \>3 years of age
Etoposide
150 mg/m2/day IV on days 1 through 5.
ALL AC220 @ 40mg/m2/day (Dose Level 2)
Dose escalation will proceed from level 1 to level 2 for AC220 at 40mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age.
AC220
Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
Cytarabine
All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day "1" of course 1 and 2. Dose defined by age:
* 20 mg for patients age \<1 yr
* 30 mg for patients age 1-1.99 years of age
* 50 mg for patients age 2-2.99 years of age
* 70 mg for patients \>3 years of age
Etoposide
150 mg/m2/day IV on days 1 through 5.
Methotrexate
IT methotrexate given intrathecally to patients with ALL on day "0" of course 1 and 2. Dose defined by age
* 6 mg for patients age \< 1yr
* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age
ALL AC220 @ 60mg/m2/day (Dose Level 3)
Dose escalation will proceed from level 2 to 3 for AC220 at 60mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. If toxicity at Dose Level 3 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
AC220
Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
Cytarabine
All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day "1" of course 1 and 2. Dose defined by age:
* 20 mg for patients age \<1 yr
* 30 mg for patients age 1-1.99 years of age
* 50 mg for patients age 2-2.99 years of age
* 70 mg for patients \>3 years of age
Etoposide
150 mg/m2/day IV on days 1 through 5.
Methotrexate
IT methotrexate given intrathecally to patients with ALL on day "0" of course 1 and 2. Dose defined by age
* 6 mg for patients age \< 1yr
* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age
ALL AC220 @ 90mg/m2/day (Dose Level 4)
If the study dose of 60 mg/m2/day at Dose Level 3 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 4 at 90 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. If toxicity at Dose Level 4 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
AC220
Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
Cytarabine
All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day "1" of course 1 and 2. Dose defined by age:
* 20 mg for patients age \<1 yr
* 30 mg for patients age 1-1.99 years of age
* 50 mg for patients age 2-2.99 years of age
* 70 mg for patients \>3 years of age
Etoposide
150 mg/m2/day IV on days 1 through 5.
Methotrexate
IT methotrexate given intrathecally to patients with ALL on day "0" of course 1 and 2. Dose defined by age
* 6 mg for patients age \< 1yr
* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age
ALL AC220 @ 130 mg/m2/day (Dose Level 5)
If the study dose of 90 mg/m2/day at Dose Level 4 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 5 at 130 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. Dose Level 5 is the highest dose for this study.
AC220
Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
Cytarabine
All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day "1" of course 1 and 2. Dose defined by age:
* 20 mg for patients age \<1 yr
* 30 mg for patients age 1-1.99 years of age
* 50 mg for patients age 2-2.99 years of age
* 70 mg for patients \>3 years of age
Etoposide
150 mg/m2/day IV on days 1 through 5.
Methotrexate
IT methotrexate given intrathecally to patients with ALL on day "0" of course 1 and 2. Dose defined by age
* 6 mg for patients age \< 1yr
* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age
AML AC220 @ 40mg/m2/day (Dose Level 2)
Dose escalation will proceed from level 1 to level 2 for AC220 at 40mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age.
AC220
Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
Cytarabine
All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day "1" of course 1 and 2. Dose defined by age:
* 20 mg for patients age \<1 yr
* 30 mg for patients age 1-1.99 years of age
* 50 mg for patients age 2-2.99 years of age
* 70 mg for patients \>3 years of age
Etoposide
150 mg/m2/day IV on days 1 through 5.
AML AC220 @ 60mg/m2/day (Dose Level 3)
Dose escalation will proceed from level 2 to 3 for AC220 at 60mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. If toxicity at Dose Level 3 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
AC220
Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
Cytarabine
All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day "1" of course 1 and 2. Dose defined by age:
* 20 mg for patients age \<1 yr
* 30 mg for patients age 1-1.99 years of age
* 50 mg for patients age 2-2.99 years of age
* 70 mg for patients \>3 years of age
Etoposide
150 mg/m2/day IV on days 1 through 5.
AML AC220 @ 90mg/m2/day (Dose Level 4)
If the study dose of 60 mg/m2/day at Dose Level 3 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 4 at 90 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. If toxicity at Dose Level 4 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
AC220
Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
Cytarabine
All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day "1" of course 1 and 2. Dose defined by age:
* 20 mg for patients age \<1 yr
* 30 mg for patients age 1-1.99 years of age
* 50 mg for patients age 2-2.99 years of age
* 70 mg for patients \>3 years of age
Etoposide
150 mg/m2/day IV on days 1 through 5.
AML AC220 @ 130mg/m2/day (Dose Level 5)
If the study dose of 90 mg/m2/day at Dose Level 4 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 5 at 130 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. Dose Level 5 is the highest dose for this study.
AC220
Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
Cytarabine
All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day "1" of course 1 and 2. Dose defined by age:
* 20 mg for patients age \<1 yr
* 30 mg for patients age 1-1.99 years of age
* 50 mg for patients age 2-2.99 years of age
* 70 mg for patients \>3 years of age
Etoposide
150 mg/m2/day IV on days 1 through 5.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AC220
Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
Cytarabine
All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day "1" of course 1 and 2. Dose defined by age:
* 20 mg for patients age \<1 yr
* 30 mg for patients age 1-1.99 years of age
* 50 mg for patients age 2-2.99 years of age
* 70 mg for patients \>3 years of age
Etoposide
150 mg/m2/day IV on days 1 through 5.
Methotrexate
IT methotrexate given intrathecally to patients with ALL on day "0" of course 1 and 2. Dose defined by age
* 6 mg for patients age \< 1yr
* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must have a diagnosis of relapsed/refractory AML, ALL or acute leukemia of ambiguous lineage and meet the following criteria:
1. Patients with AML or leukemia with ambiguous lineage must have greater than or equal to 5% blasts in the bone marrow.
2. Patients with ALL must have an M3 marrow (marrow blasts \>25%).
3. Patients with ALL must have MLL gene rearrangement or hyperdiploid \>50 chromosomes.
4. Patients with treatment related AML (t-AML) are eligible, provided they meet all other eligibility criteria.
* Karnofsky \> 50% for patients \>16 years of age and Lansky \>50% for patients ≤16 years of age.
* Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
* Myelosuppressive chemotherapy:
* Patients with ALL who relapse during standard maintenance therapy are eligible at time of relapse.
* For patients with ALL and AML who relapse while they are receiving cytotoxic therapy, at least 14 days must have elapsed since the completion of cytotoxic therapy.
* Cytoreduction with hydroxyurea can be initiated and continued for up to 24 hours prior to the start of AC220.
* Patients who have received other FLT3 inhibitors (ex. lestaurtinib, sorafenib) are eligible for this study.
* Hematopoietic growth factors: At least 7 days since the completion of therapy with a growth factor.
* Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair.
* XRT: 2 wks must have elapsed since local palliative XRT for CNS chloromas; No washout period is necessary for other chloromas; at least 3 months must have elapsed if prior TBI, craniospinal XRT.
* Hematopoetic Stem Cell Transplant: At least 90 days must have elapsed since hematopoietic stem cell transplant (HSCT) and patients must not have active GVHD.
* Patient must have adequate renal and hepatic functions as indicated by the following laboratory values:
* Patients must have a calculated creatinine clearance or radioisotope GFR ≥70mL/min/1.73m2 or a normal serum creatinine based on age/gender.
* Total bilirubin \<1.5 x ULN for age or normal conjugated bilirubin.
* Alanine transaminase (ALT) \<5 × ULN (unless related to leukemic involvement).
* Patient must have a shortening fraction of ≥ 27% by echocardiogram, OR an ejection fraction of ≥ 50% by radionuclide angiogram.
* Reproductive Function
* Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed within 2 weeks prior to enrollment.
* Female patients with infants must agree not to breastfeed their infants while on this study.
* Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for a minimum of 6 months after study treatment.
Exclusion Criteria
* Patients will be excluded if they have uncontrolled or significant cardiovascular disease, including:
* A myocardial infarction within 12 months.
* Uncontrolled angina within 6 months.
* Diagnosed or suspected congenital long QT syndrome or any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes \[TdP\]); any history of arrhythmia will be discussed with the Sponsor's Medical Monitor prior to patient's entry into the study.
* Prolonged QTcF interval on pre-entry ECG (≥450 ms).
* Any history of second or third degree heart block (may be eligible if the patient currently has a pacemaker).
* Heart rate \< 50/minute on pre-entry ECG.
* Uncontrolled hypertension.
* Complete left bundle branch block.
* Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or TdP.
* Patients will be excluded if they have a systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment. The patient needs to be off pressors and have negative blood cultures for 48 hours.
* Patient is receiving or plans to receive concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.
* Any significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.
* Patients who are concurrently receiving CYP3A4 and 5 inhibitors and inducers
1 Month
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ambit Biosciences Corporation
INDUSTRY
Therapeutic Advances in Childhood Leukemia Consortium
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Todd Cooper, MD
Role: STUDY_CHAIR
Children's Healthcare of Atlanta, Emory University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Childrens Hospital Los Angeles
Los Angeles, California, United States
Children's Hospital Central California
Madera, California, United States
UCSF School of Medicine
San Francisco, California, United States
The Children's Hospital, University of Colorado
Aurora, Colorado, United States
Children's Healthcare of Atlanta, Emory University
Atlanta, Georgia, United States
Johns Hopkins University
Baltimore, Maryland, United States
Dana Farber
Boston, Massachusetts, United States
Children's Mercy Hospitals and Clinics
Kansas City, Missouri, United States
Levine Children's Hospital at Carolinas Medical Center
Charlotte, North Carolina, United States
Oregon Health and Science University
Portland, Oregon, United States
Seattle Children's Hospital
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, Chang BH, Gore L, August K, Pollard JA, DuBois SG, Silverman LB, Oesterheld J, Gammon G, Magoon D, Annesley C, Brown PA. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clin Cancer Res. 2016 Aug 15;22(16):4014-22. doi: 10.1158/1078-0432.CCR-15-1998. Epub 2016 Feb 26.
Related Links
Access external resources that provide additional context or updates about the study.
Therapeutic Advances in Childhood Leukemia \& Lymphoma Consortium web site
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
T2009-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.